filmov
tv
Pathologist's Perspective on Focal Therapy
Показать описание
M. Scott Lucia, MD, Professor and Vice Chair of the Department of Pathology and Director of Anatomic Pathology of the Prostate Diagnostic Laboratory at the University of Colorado Anschutz Medical Campus (CAMC) School of Medicine reviews study data to help physicians decide which biopsy route is best when selecting patients for focal therapy. Using results from the SEER, PROMIS, and PRECISION studies, among others, he argues that TRUS biopsies are insufficient and miss too many high-grade tumors, while TTMP plus mpMRI guided biopsy appears to provide the most accurate results.
Pathologists Perspective on Focal Therapy
Pathologist's Perspective on Focal Therapy
Mapping Pathology as a Guide to Focal Therapy The Role of Mapping Biopsies and Tissue Markers
Pathologist's Perspective on Biopsy Results: Transperineal Mapping vs. Fusion Biopsy
Is Focal Ablation of Prostate Cancer Ready for Prime Time
How to Utilize MRI for Focal Therapy Planning
Radiation vs. Focal Therapy: Dr. Timothy McClure Breaks Down Prostate Cancer Treatments
HIFU Focal Therapy: Prostate Cancer - Emerging Data and Clinical Utility vs. Standard Care
MRI-Guided Focal Therapy: Initial Quality-of-Life and Oncologic Outcomes
Imaging and Biomarkers in Patient Selection for Focal Ablation
To the Point: Focal or Definitive Therapy for Prostate Cancer: MRI vs. Mapping Part II
(13) Path Towards Focal Therapy of Prostate Cancer at UCLA
Focal Therapy Society: Prostate Cancer Epidemiology and Active Surveillance. A Do Not Miss Session.
Changing Distribution, Size and Grade of Prostate Cancer
Focal Therapy in Prostate Cancer
MRI/US Fusion Biopsy
Focal Therapy with Professor Phillip Stricker AO
What's New in Active Surveillance for Prostate Cancer
Application of MRI Fusion Biopsy Results to Focal Therapy
Comprehensive Review: Focal Therapy Follow-Up, Complications, and Advanced Imaging Techniques
(4) AUA 2017 Best Video: From Targeted Biopsy To Focal Therapy of Prostate Cancer
Brachytherapy and Focal Therapy Outcomes
KEYNOTE LECTURE: Too Little or Just Enough? The Role of Focal Therapy in ProtecT Era
Low Risk (Gleason 3+3=6) & Intermediate Risk (Gleason 3+4=7) Prostate Cancer Q+A | PCRI #13
Комментарии